Controversies in Neuro-Oncology

Avastin and Malignant Gliomas

Indexed in: Chemical Abstracts, EBSCO, Ulrich's Periodicals Directory.

Neuro-oncology is an embryonic field of cancer research with a number of clinical trials in progress. However, the prognosis on neuro-oncologic patients has remained poor. Moreover, several small ...
[view complete introduction]

US $
30

*(Excluding Mailing and Handling)



Assessing Radiographic Response to Bevacizumab in Patients with GBM

Pp. 94-99 (6)

John W. Henson and Bart Keogh

Abstract

Abnormal gadolinium enhancement has been the standard characteristic for the measurements of brain tumors in clinical trials, but new therapies that target the vascular components of tumors have highlighted the shortcomings of enhancement as a measurement tool. Inhibitors of vascular endothelial growth factor (VEGF), such as bevacizumab, can produce rapid changes in the degree of contrast enhancement within malignant gliomas and in the extent of surrounding hyperintense T2-weighted signal. These effects, which are consistent with decreasing permeability of tumor capillaries, make it exceedingly difficult to employ conventional measures of tumor size in the setting of clinical trials. This chapter will review these issues and describe approaches to tumor measurement in the era of VEGF inhibitors.

Affiliation:

Neuroradiology, Swedish Neuroscience Institute, and 3Radia PS, Seattle, WA.